Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc.ANEB · Entity 9617 | Chief Scientific Officer | April 04, 2025 | April 08, 2025 |
| CohBar, Inc.CWBR · Entity 124935 | Chief Scientific Officer | August 11, 2021 | August 13, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anebulo Pharmaceuticals, Inc.
Report date April 04, 2025 · Filed April 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2035-04-03 | Direct | 115,037 |
Reported balance
After 2025-04-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-04 · Grant · Acquired 115,037 · Balance 115,037 F1: One-sixteenth (1/16) of the shares subject to the option vested and became exercisable on April 4, 2025, with the remainder scheduled to vest and become exercisable in fifteen (15) equal quarterly installments on each July 15, October 15, January 15, and April 15 thereafter, vesting fully on January 15, 2029, in each case, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-sixteenth (1/16) of the shares subject to the option vested and became exercisable on April 4, 2025, with the remainder scheduled to vest and become exercisable in fifteen (15) equal quarterly installments on each July 15, October 15, January 15, and April 15 thereafter, vesting fully on January 15, 2029, in each case, subject to the Reporting Person's continued service to the Issuer through each vesting date.
CohBar, Inc.
Report date August 11, 2021 · Filed August 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Ending reported balance
After 2021-08-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-08-11 · Exercise / conversion · Acquired 10,000 · Balance 20,000 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Row 2 · 2021-08-11 · Sale · Disposed 10,000 · Balance 10,000 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2: Represents the weighted average sale price. The lowest price at which shares were sold was $2.01 and the highest price at which shares were sold was $2.02. The Reporting Person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2024-11-17 | Direct | 750,000 |
Reported balance
After 2021-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-08-11 · Exercise / conversion · Disposed 10,000 · Balance 750,000 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3: The options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: Represents the weighted average sale price. The lowest price at which shares were sold was $2.01 and the highest price at which shares were sold was $2.02. The Reporting Person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.
F3: The options are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 28, 2019 Filed Oct 30, 2019 16:05 UTC | CohBar, Inc. CWBR · Entity 124935 | Exercise / conversionCommon Stock | 103 | $1.90 | $195.70 |
DisclosureSEC source: 0001213900-19-021510 · ownership.xml · nonDerivative · entry 1 Cundy Kenneth C · CIK 0001322959 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 18:32 UTC | CohBar, Inc. CWBR · Entity 124935 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001209191-18-043541 · doc4.xml · derivative · entry 1 Cundy Kenneth C · CIK 0001322959 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-01-29 F1 · derivative.exercise_date: On January 29, 2017, the reporting person was granted an option to purchase 500,000 shares of common stock. Half of the shares subject to the option are subject to vesting based upon the achievement of certain company performance goals. The remaining shares subject to the option are subject to vesting ratably over a period of 24 months following achievement of the performance goals, subject to the continued employment of the reporting person during such period. The performance goals were achieved, resulting in the vesting of 250,000 shares subject to the option as of July 18, 2018. The remaining shares will vest ratably over a period of 24 months from July 18, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.